Novartis' MS Drug Gilenya Under FDA Investigation for PML Case - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis' MS Drug Gilenya Under FDA Investigation for PML Case
FDA has issued a safety alert after a patient with multiple sclerosis (MS) in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy (PML) following treatment with Gilenya (fingolimod).



FDA has issued issued a safety alert after a patient with multiple sclerosis (MS) in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy (PML) following treatment with Gilenya (fingolimod). According to the agency, this is the first case of PML in a patient taking Gilenya who had not previously received Tysabri (natalizumab, marketed by Biogen Idec), which is an MS drug associated with a higher risk of PML.

FDA warns patients not to stop taking Gilenya without consulting their doctors. FDA is working with Novartis to investigate this case and will review all available information about this occurrence. The final conclusions and recommendations will be announced after completion of the evaluation.

Gilenya was approved in 2010 as the first oral treatment for relapsing forms of MS and approximately 71,000 patients worldwide have been treated since its launch, according to Novartis. Novartis first reported this new case of PML in July.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here